Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management

MedXY Editorial Team•Nov 13, 2025•Clinical Updates

Elinzanetant is a first-in-class, non-hormonal small molecule antagonist targeting neurokinin 1 and 3 receptors (NK1 and NK3), developed by Bayer for vasomotor symptoms (VMS) of menopause.
In July 2025, it was approved in the United Kingdom, followed by FDA approval in October 2025 for moderate-to-severe menopausal VMS, marking a major advance in menopause management.
Robust evidence from phase 2b and pivotal phase 3 trials (SWITCH-1 and OASIS 1/2) demonstrated statistically significant reductions in VMS frequency and severity, along with improvements in sleep disturbances and quality of life.
Mechanistic studies confirm elinzanetant’s dose-dependent suppression of reproductive hormone levels (estradiol, progesterone) without inducing vasomotor symptoms in healthy women, supporting its novel pharmacological profile.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Elinzanetant is a first-in-class, non-hormonal small molecule antagonist targeting neurokinin 1 and 3 receptors (NK1 and NK3), developed by Bayer for vasomotor symptoms (VMS) of menopause.
In July 2025, it was approved in the United Kingdom, followed by FDA approval in October 2025 for moderate-to-severe menopausal VMS, marking a major advance in menopause management.
Robust evidence from phase 2b and pivotal phase 3 trials (SWITCH-1 and OASIS 1/2) demonstrated statistically significant reductions in VMS frequency and severity, along with improvements in sleep disturbances and quality of life.
Mechanistic studies confirm elinzanetant’s dose-dependent suppression of reproductive hormone levels (estradiol, progesterone) without inducing vasomotor symptoms in healthy women, supporting its novel pharmacological profile.